Polaris Group (TWSE:6550) rush to the stock exchange to apply for the first listing of shares before the end of 2021! Polaris Group submitted an application for listing on the 27th. It is the second foreign company to apply for the first listing in this (2021) year.
Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine.
Polaris Group (TWSE:6550) announced today that Dr. Philip Felgner of the University of California, Irvine will officially join the Polaris Technical Advisory Board on September 1.
Polaris Pharmaceuticals announced today that Dr. Yali Tsai has joined Polaris as Vice President of Gene Delivery Technology. With over 25 years of hands-on experience in drug delivery technology and manufacturing, Dr. Tsai has developed a wide range of drugs, including injectable drugs, ophthalmic drugs and skin drugs, and has extensive experience in the development of specialty dosage forms such as microlipids, nanoemulsions and suspension particles.
Polaris Group (TWSE:6550) held its 2021 Annual General Meeting on August 23, announcing the launch of the world’s first Phase III clinical trial for a single-agent liver cancer treatment using genetic biomarker screening. The Polaris R&D team analyzed the genes of patients who had previously participated in liver cancer clinical trials and discovered that liver cancer patients with specific genetic markers demonstrated significant therapeutic efficacy when treated with ADI.
After consultation with FDA, Polaris will follow Data and Safety Monitoring Board’s (DSMB) recommendation to stop Phase III study in lung mesothelioma due to current success and difficulty in continued enrollment
2021/04/04-Polaris Group Polaris Pharmaceuticals-KY(6550TW) announces, Due to the impressive results of the Phase II clinical trial in soft tissue tumors, the trial host has been invited to give a live presentation in the most prestigious “oral presentation” format at the 2021 American Society for Clinical Oncology (ASCO).
Based on the data at the interim analysis of Feb 25, 2021, it is estimated that the chance for success, that the survival benefit of ADI PEG-20 over the control group is statistically significant at the end of the trial, will be greater than 80%.
Polaris Group (TW:6550) released its interim analysis report for the Phase III clinical trial of pleural mesothelioma (a type of lung cancer) in the United States on February 25 (U.S. time).
Nanotein Technologies, Inc., an innovative startup biotechnology company in the San Francisco Bay Area, and Polaris Group, a developer of novel treatments for cancer, announced today they have entered into a strategic partnership to advance Nanotein’s protein-based solutions for superior cellular therapy manufacturing.
